Epidemiology & public health

Hospital wastewater (HWW) poses a significant environmental and health risk due to the presence of pharmaceuticals, pathogens, and other hazardous substances that are administered in healthcare institutions. Unfortunately, current urban wastewater treatment (WWT) plants are not capable of effectively removing many of the pollutants generated by hospitals. As a result, these contaminants reach and accumulate in natural water bodies, threatening ecosystems and biodiversity, and public health through the contamination of drinking water or food. In addition, public health is also menaced by HWW as it contains important amounts of antibiotic-resistant microorganisms and genes. In fact, Antimicrobial Resistance (AMR) is one of the greatest health threats of our times. 

The main objective of THERESA PCP is the development of a “green” and innovative solution to treat HWW.
The technology developed within the project will help to reduce the environmental impact of the healthcare sector and to protect public health from emerging contaminants. This will be done by creating a network of procuring organizations and experts through the execution of a joint PCP.

CancerWatch JA aims to address cancer registry quality and timeliness and make the data-driven insights available via the ECIS as well as the emerging European Health Data Space infrastructure. The European Cancer Inequalities Registry will also benefit from better registry data. This Joint Action will be identifying opportunities to improve operation of the registries and their means to utilize digital methods to capture cancer data residing in the healthcare organizations. It will address harmonized means to measure quality and facilitate data access and finally, it will provide means to provide indicators on the burden of cancer via the ECIS.

This project has received funding from the European Union’s EU4Health programme under grant agreement No 101219450.

El proyecto EMERGENTcy es la continuación del proyecto OUTBIOTICS, que se centró en la presencia de antibióticos de origen animal en ríos del territorio POCTEFA y en tecnologías para su eliminación. EMERGENTcy presenta un enfoque público, desde salud y medio ambiente, centrándose en antibióticos, otros CE, ARBs y ARGs en el CUA aprovechando la red de EAR creada durante la pandemia. Se probará la tecnología testada para eliminar CE a mayor TRL y se trabajará en la sensibilización y en una nueva legislación regional.

El proyecto EMERGENTcy está cofinanciado al 65% por la Unión Europea a través del Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). El objetivo del POCTEFA es reforzar la integración económica y social de la zona fronteriza España-Francia-Andorra. Así, el proyecto EMERGENTcy da continuidad al proyecto OUTBIOTICS cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER) a través del Programa Interreg V-A España-Francia-Andorra (POCTEFA 2014-2020).

Entidad líder:
		​				​
Entidades participantes:
​				​		​

To combat Antimicrobial resistance (AMR), a global approach is called for, combining awareness raising, surveillance, antimicrobial stewardship (AMS), infection prevention/control (IPC) while ensuring access to antibiotics and diagnostics. Such interventions need to be grounded in a One Health perspective, considering the interconnection between humans, animals and the environment. Following the 2017 EU One Health Action Plan against AMR to make Europe a best practice region and the first European Joint Action (JA) on AMR and Healthcare-Associated Infections (EU-JAMRAI), this new JA, EU-JAMRAI 2, will support Member States/Associated Countries (MS/AC) in their efforts to develop and update their National Action Plan (NAP) on AMR.

This project has received funding from the European Union’s EU4Health programme under grant agreement No 101127787.

The aim of the project is to consolidate a national laboratory network (RELECOV) for a sustainable and collaborate platform to obtain virological information about SARS-CoV-2 variants/lineages for the integration of the genomic sequencing in the surveillance of SARS-CoV-2. Efforts will focus on constructing a national platform for genomic surveillance applied to respiratory viral infection, rapidly adaptable to other future emerging pathogens and contributing to international pandemic preparedness. Through protocol sharing and pooling of results at national level, questions will be answered more efficiently than by the Autonomous Regions acting alone.

This project has received funding from the European Union’s EU4Health programme under grant agreement No 101113109.

ORGANISMO FINANCIADOR:

The European Union is working tirelessly to ensure that all Europeans have access to COVID-19 vaccines as soon as possible. The licensed vaccines are effective against the current virus. At the same time, we must prepare for new variants of the virus by rapidly developing and producing vaccines effective against these variants on a large scale. This is why the European Commission has launched the HERA incubator. The aim is to bring together science, industry and public authorities, harnessing all available resources to enable Europe to respond to this threat.

The European Union is working tirelessly to ensure that all Europeans have access to COVID-19 vaccines as soon as possible. The licensed vaccines are effective against the current virus. At the same time, we must prepare for new variants of the virus by rapidly developing and producing vaccines effective against these variants on a large scale. This is why the European Commission has launched the HERA incubator. The aim is to bring together science, industry and public authorities, harnessing all available resources to enable Europe to respond to this threat.

FUNDING ORGANISATION: